Current Pipeline Status

AC2993 Phase 2 - T2 Diabetes

AC2993 LAR Phase 1

AC3056 Phase 1

SYMLIN™ (pramlintide acetate)
• T1 and insulin-using T2 diabetes
• Currently under review by FDA
• Advisory Committee meeting 7/26
• MAA submitted in May 2001

AMYLIN’S BUSINESS MODEL

Previous slide

Next slide

Back to first slide

View graphic version